Nasal Polyposis Treatment Market to reach US$ 8.8 billion by 2033, Corticosteroids to Constitute 55% of all Treatments: Future Market Insights, Inc. Report
27. März 2023 08:30 ET
|
Future Market Insights Global and Consulting Pvt. Ltd.
NEWARK, Del, March 27, 2023 (GLOBE NEWSWIRE) -- The global Nasal Polyposis Treatment Market is expected to reach US$ 4.6 billion in value terms by 2023-end and is projected to rise at a CAGR of 6.7%...
Global Nasal Spray Market Is Expected to Reach $16.9 Billion by 2031: Allied Market Research
16. März 2023 10:30 ET
|
Allied Market Research
Portland, OR, March 16, 2023 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global Nasal Spray Market generated $9.2 billion in 2021, and is estimated to reach...
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
28. Februar 2023 16:30 ET
|
Optinose, Inc.
YARDLEY, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
08. Juli 2022 07:00 ET
|
Optinose, Inc.
Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis Multiple secondary endpoints from...
Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
15. November 2021 16:26 ET
|
Optinose, Inc.
Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020 Third quarter 2021 XHANCE prescriptions increased 25% from third quarter 2020 Conference call and...
Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
11. August 2021 07:00 ET
|
Optinose, Inc.
Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020 Second quarter 2021 XHANCE prescriptions increased 33% from second quarter 2020 Conference call...
Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation
28. April 2021 08:30 ET
|
Optinose, Inc.
Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 YARDLEY, Pa., April 28, 2021...